BACKGROUND. Studies using clinical measures to track AD progression often assume linear declines over the entire course of the disease, which may not be justified. The objective of this study was to model change in measures of the clinical severity of Alzheimer's disease (AD) over time. METHODS. We developed a method to apply growth curve models to prospective data and characterize AD patients' functional change over time. Data from the modified Mini-Mental State Examination (mMMSE) and measures of basic and instrumental ADL, administered semiannually for up to 5 years to 236 patients with probable AD, were modeled. RESULTS. The rate of decline in mMMS scores per 6-month interval gradually increased as scores dropped from the maximum of 57 ...
Background: Alzheimer’s disease (AD) is associated with variable cognitive and functional decline, ...
Background: The course of Alzheimer’s disease (AD) varies considerably between individuals. There is...
Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and ...
Objective: To determine how the advent of extrapyramidal signs influences the progression of Alzheim...
BACKGROUND: The characterizing symptom of Alzheimer disease (AD) is cognitive deterioration. While m...
OBJECTIVE: To consider the methods available to model Alzheimer's disease (AD) progression over time...
Background: Different rates of cognitive progression have been observed among Alzheimer disease (AD...
Mahesh N Samtani, Nandini Raghavan, Gerald Novak, Partha Nandy, Vaibhav A Narayan On behalf of the A...
Appropriate planning for the future functional decline of patients with Alzheimer’s disease (AD) is ...
Background: Different rates of cognitive progression have been observed among Alzheimer disease (AD)...
Background: Previous studies revealed that cognitive test scores were related to functional outcome ...
Longitudinal designs are often used for studying the natural history of diseases. Data sets typicall...
Analyzing the progression of Alzheimer's disease (AD) is challenging due to lacking sensitivity in c...
BACKGROUND: Different rates of cognitive progression have been observed among Alzheimer disease (AD...
AbstractObjectiveTo consider the methods available to model Alzheimer's disease (AD) progression ove...
Background: Alzheimer’s disease (AD) is associated with variable cognitive and functional decline, ...
Background: The course of Alzheimer’s disease (AD) varies considerably between individuals. There is...
Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and ...
Objective: To determine how the advent of extrapyramidal signs influences the progression of Alzheim...
BACKGROUND: The characterizing symptom of Alzheimer disease (AD) is cognitive deterioration. While m...
OBJECTIVE: To consider the methods available to model Alzheimer's disease (AD) progression over time...
Background: Different rates of cognitive progression have been observed among Alzheimer disease (AD...
Mahesh N Samtani, Nandini Raghavan, Gerald Novak, Partha Nandy, Vaibhav A Narayan On behalf of the A...
Appropriate planning for the future functional decline of patients with Alzheimer’s disease (AD) is ...
Background: Different rates of cognitive progression have been observed among Alzheimer disease (AD)...
Background: Previous studies revealed that cognitive test scores were related to functional outcome ...
Longitudinal designs are often used for studying the natural history of diseases. Data sets typicall...
Analyzing the progression of Alzheimer's disease (AD) is challenging due to lacking sensitivity in c...
BACKGROUND: Different rates of cognitive progression have been observed among Alzheimer disease (AD...
AbstractObjectiveTo consider the methods available to model Alzheimer's disease (AD) progression ove...
Background: Alzheimer’s disease (AD) is associated with variable cognitive and functional decline, ...
Background: The course of Alzheimer’s disease (AD) varies considerably between individuals. There is...
Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and ...